Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q2 FY22 results · Jul–Sep 2021
Dr. Lal Path Labs reported revenue from operations of ₹498.40 crore (up 15.4% from Q2 FY21) and net profit of ₹96.30 crore (up 10.6% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 498.40 | 431.90 | +15.4% | 606.60 | −17.8% |
| Other income | 14.30 | 12.90 | +10.9% | 14.10 | +1.4% |
| Total income | 512.70 | 444.80 | +15.3% | 620.70 | −17.4% |
| Profit before tax | 130.60 | 116.60 | +12.0% | 179.30 | −27.2% |
| Net profit for the period | 96.30 | 87.10 | +10.6% | 133.70 | −28.0% |
| Attributable to shareholders of the company | 95.00 | 85.30 | +11.4% | 131.20 | −27.6% |
| EPS, basic (₹) | 11.49 | 10.34 | +11.1% | 15.87 | −27.6% |
| Net margin (%) | 19.3 | 20.2 | 22.0 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 470.40 | 404.30 | +16.3% | 564.90 | −16.7% |
| Other income | 15.30 | 12.50 | +22.4% | 13.50 | +13.3% |
| Total income | 485.70 | 416.80 | +16.5% | 578.40 | −16.0% |
| Profit before tax | 125.90 | 106.80 | +17.9% | 165.20 | −23.8% |
| Net profit for the period | 93.90 | 79.90 | +17.5% | 123.30 | −23.8% |
| EPS, basic (₹) | 11.36 | 9.68 | +17.4% | 14.93 | −23.9% |
| Net margin (%) | 20.0 | 19.8 | 21.8 |
Consolidated
- Filed with BSE
- 27 Oct 2021, 08:53 IST
- Board meeting
- 26 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Oct 2021, 08:53 IST
- Board meeting
- 26 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE